FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667410> ?p ?o ?g. }

• W4385667410 endingPage "e2943794" @default.
• W4385667410 startingPage "e2943794" @default.
• W4385667410 abstract "Topic: 26. Sickle cell disease Background: Deferiprone (DFP) is an oral iron chelator indicated for transfusional iron overload. It was initially approved by the US Food & Drug Administration (FDA) in 2011 for patients with thalassemia, and later expanded to patients with sickle cell disease (SCD) in 2021. Prior to expanded approval, DFP was prescribed off-label to patients with SCD. The Ferriprox Total Care Registry was an active drug surveillance program for DFP established in the US as a post-marketing requirement in 2011. The data collected from the registry enrich existing clinical trial data and help characterize the long-term safety of DFP in clinical practice. Aims: To evaluate DFP’s long-term safety profile in US patients with SCD in a real-world registry. Methods: For this retrospective analysis, we extracted data from the Ferriprox Total Care Registry for US patients with SCD receiving DFP between December 5, 2011, and August 31, 2020. Following enrolment, a central pharmacy contacted patients monthly to inquire about their well-being and collected information about any adverse event (AE) or serious AE (SAE; any medical occurrence that was life-threatening, required hospitalization, caused persistent disability, or needed intervention to prevent permanent damage) reported by the patient, regardless of relationship to treatment Results: The Registry included 634 patients with SCD (58.7% female; mean age 32.8 [SD 16.3] years [range 4–78]) receiving DFP for a mean of 1.6 years (SD 1.6; range 0.0–9.7) totalling 1023.9 patient-years of treatment. About one-fifth of patients (n=130; 20.5%) were paediatric (age ≤17 years). At the cutoff date, 180 patients (28.4%) were still receiving DFP, 434 patients (68.5%) had been discharged from the registry, and 20 patients (3.2%) had not yet initiated treatment. Patients were most commonly discharged from the registry at the physician’s direction (19.2%) or because of AEs (12.6%), switching to another iron chelator (10.7%), or death (7.4%). Among 80 patients who discontinued DFP due to AEs, the most common reasons were nausea (n=31; 4.9%), vomiting (n=20; 3.2%), and sickle cell crisis (SCC; n=19; 3.0%). Among 130 paediatric patients, few discontinued due to AEs (n=8; 6.2%), most commonly because of pyrexia (n=2) and abdominal discomfort (n=2); these were deemed unrelated to DFP treatment. A total of 410 patients (64.7%) reported 1885 AEs, and 267 patients (42.1%) reported 1035 SAEs. The most common AEs (Table) were SCC (336 events) and nausea (84 events), and the most common SAEs were SCC (336 events) and pneumonia (30 events). Overall, 2 (0.3%) patients reported agranulocytosis (neutrophil count < 0.5 x 109/L), and 4 (0.6%) patients reported neutropenia (neutrophil count between ≥ 0.5 x 109/L and < 1.49 x 109/L). During the study period, 27 deaths were reported as AEs, and the reported causes of death were often related to potential SCD complications. Summary/Conclusion Based on ~10 years of safety data from the US registry of patients receiving DFP, DFP was well tolerated in both adult and paediatric patients with SCD. Notably, few patients reported neutropenia or agranulocytosis, which are considered the most concerning potential SAEs associated with DFP. Importantly, no new safety concerns were identified, which was consistent with clinical trials, previous real-world observations, and the known safety profile of DFP in thalassemia.Keywords: Real world data, Iron chelation, Sickle cell disease, Iron overload" @default.
• W4385667410 created "2023-08-09" @default.
• W4385667410 creator A5023558478 @default.
• W4385667410 creator A5030306815 @default.
• W4385667410 creator A5038535078 @default.
• W4385667410 creator A5049912487 @default.
• W4385667410 creator A5067531512 @default.
• W4385667410 creator A5079102665 @default.
• W4385667410 creator A5090965296 @default.
• W4385667410 date "2023-08-01" @default.
• W4385667410 modified "2023-09-27" @default.
• W4385667410 title "P1442: PRACTICE-BASED EVIDENCE: LONG-TERM SAFETY COHORT OF DEFERIPRONE IN PATIENTS WITH SICKLE CELL DISEASE FROM THE US REGISTRY" @default.
• W4385667410 doi "https://doi.org/10.1097/01.hs9.0000972652.29437.94" @default.
• W4385667410 hasPublicationYear "2023" @default.
• W4385667410 type Work @default.
• W4385667410 citedByCount "0" @default.
• W4385667410 crossrefType "journal-article" @default.
• W4385667410 hasAuthorship W4385667410A5023558478 @default.
• W4385667410 hasAuthorship W4385667410A5030306815 @default.
• W4385667410 hasAuthorship W4385667410A5038535078 @default.
• W4385667410 hasAuthorship W4385667410A5049912487 @default.
• W4385667410 hasAuthorship W4385667410A5067531512 @default.
• W4385667410 hasAuthorship W4385667410A5079102665 @default.
• W4385667410 hasAuthorship W4385667410A5090965296 @default.
• W4385667410 hasBestOaLocation W43856674101 @default.
• W4385667410 hasConcept C104863432 @default.
• W4385667410 hasConcept C126322002 @default.
• W4385667410 hasConcept C187212893 @default.
• W4385667410 hasConcept C194828623 @default.
• W4385667410 hasConcept C195910791 @default.
• W4385667410 hasConcept C197934379 @default.
• W4385667410 hasConcept C2776517179 @default.
• W4385667410 hasConcept C2777799968 @default.
• W4385667410 hasConcept C2778959093 @default.
• W4385667410 hasConcept C2779134260 @default.
• W4385667410 hasConcept C512399662 @default.
• W4385667410 hasConcept C535046627 @default.
• W4385667410 hasConcept C71924100 @default.
• W4385667410 hasConcept C72563966 @default.
• W4385667410 hasConceptScore W4385667410C104863432 @default.
• W4385667410 hasConceptScore W4385667410C126322002 @default.
• W4385667410 hasConceptScore W4385667410C187212893 @default.
• W4385667410 hasConceptScore W4385667410C194828623 @default.
• W4385667410 hasConceptScore W4385667410C195910791 @default.
• W4385667410 hasConceptScore W4385667410C197934379 @default.
• W4385667410 hasConceptScore W4385667410C2776517179 @default.
• W4385667410 hasConceptScore W4385667410C2777799968 @default.
• W4385667410 hasConceptScore W4385667410C2778959093 @default.
• W4385667410 hasConceptScore W4385667410C2779134260 @default.
• W4385667410 hasConceptScore W4385667410C512399662 @default.
• W4385667410 hasConceptScore W4385667410C535046627 @default.
• W4385667410 hasConceptScore W4385667410C71924100 @default.
• W4385667410 hasConceptScore W4385667410C72563966 @default.
• W4385667410 hasIssue "S3" @default.
• W4385667410 hasLocation W43856674101 @default.
• W4385667410 hasLocation W43856674102 @default.
• W4385667410 hasOpenAccess W4385667410 @default.
• W4385667410 hasPrimaryLocation W43856674101 @default.
• W4385667410 hasRelatedWork W2076765587 @default.
• W4385667410 hasRelatedWork W2103931355 @default.
• W4385667410 hasRelatedWork W2118942391 @default.
• W4385667410 hasRelatedWork W2186181683 @default.
• W4385667410 hasRelatedWork W2411443293 @default.
• W4385667410 hasRelatedWork W2440502035 @default.
• W4385667410 hasRelatedWork W2603773853 @default.
• W4385667410 hasRelatedWork W4244128297 @default.
• W4385667410 hasRelatedWork W1795864173 @default.
• W4385667410 hasRelatedWork W2166844718 @default.
• W4385667410 hasVolume "7" @default.
• W4385667410 isParatext "false" @default.
• W4385667410 isRetracted "false" @default.
• W4385667410 workType "article" @default.